Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologyAssociation of Circulating Tumor DNA Dynamics w. Clinical Outcomes in the Adjuvant Setting for Patients w. CRC from an Observational GALAXY Study in CIRCULATE – Japan

Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) might be used to identify patients who would benefit more from standard-of-care adjuvant chemotherapy by accurately assessing recurrence-risk post-surgery and by evaluating adjuvant chemotherapy efficacy. This analysis from the GALAXY study, an observational study monitoring MRD, evaluates the association of ctDNA dynamics with a short-term clinical outcome and ACT efficacy.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form